

PATENTS

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application of

Jean Plouet et al.

Serial No. 09/091,561

GROUP 1644

Filed August 21, 1998

Examiner G. Ewoldt

ANTI-IDIOTYPIC ANTIBODIES OF  
VASCULAR ENDOTHELIAL GROWTH  
FACTOR AND USE THEREOF AS DRUGS



Rule 132 Declaration of Dr. Jean Plouet

I, Jean Plouet, hereby declare as follows :

I am the same Jean Plouet named as an inventor in the above-identified patent application. My relevant background and experience are set forth on the attached c.v. I make this declaration in support of the present application, and to provide evidence in rebuttal of several contentions in the Official Action of May 10, 2000, that various claims of this patent application would have been obvious from the applied prior art.

In 1989, we had prepared polyclonal antibodies in rabbits against murine VEGF purifies as described in Plouët et al, EMBO J, 1989. These antibodies proved to be neutralizing for the binding of iodinated VEGF to endothelial cells and for the proliferation and migration of endothelial cell induced by VEGF.

Since it was impossible to decipher the functions mediated *in vivo* by each VEGF receptor because (i) VEGF does not circulate (ii) the VEGF receptors were not identified, we decided to construct circulating agonists of VEGF receptors, in order to :

- purify and characterize VEGF receptors,
- decipher the biological functions exerted by each VEGF receptor.

In winter 1992, we injected subcutaneously these anti-murine VEGF antibodies to rabbits, and therefore raised anti-idiotypic antibodies described in the abstract published in the Journal of Cellular Biochemistry, January 4-23, 1994 ("the 1994 Abstract").

The properties that we discovered about these antibodies are that :

- they acted as agonists of the VEGF receptors,
- they induced proliferation and migration,
- they were not internalized.

At the time of the filing of this patent application, it had been demonstrated that VEGF binds to vascular endothelial cells on two distinct binding sites, one with a Kd of 2-10 pM and another one with a Kd of 50-100 pM (Plouët, Biochimie, 1990 ; Plouët, J Biol Chem, 1990). However, it is not clear, even today, that one site could correspond to one receptor, especially when considering the differences between *in vivo* and *in vitro* situations. We also demonstrated that VEGF was able to bind to non endothelial cells such as lens epithelial cells or corneal endothelial cells on a single site with a Kd of 5-10 pM. These non-endothelial cells did not proliferate under VEGF addition, but migrate. Similarly, we showed that "In vivo, VAS/VEGF (VAS, for vasculotropin, was the previous name of VEGF) was recognized as an inducer of angiogenesis and vascular permeability. In vitro, despite a moderate action on proliferation, VAS/VEGF strongly stimulates the cell migration" (Favard,..., Plouet et al, Bio Cell 1991).

Our interpretation at this time, and is still true today, was that this production of anti-idiotypic antibodies was not specific of a single VEGF receptor, even though we had hoped that, among so far unknown VEGF receptors, one should mediate migration, another one proliferation. The VEGF receptor *flt-1* had been cloned in 1992 (De Vries, Science 1992), with indications that *flt-1* was expressed in endothelium during neovascularization of healing skin wounds and during early vascular development in mouse embryos. The receptor KDR and its murine homologue *flk-1* had been released to public knowledge only in 1993 (Quinn et al, Proc. Natl. Acad. Sci., 1993), at the time of the submission of the 1994 Abstract to the January 1994 Keystone Symposium. In this Quinn 1993 publication, it was demonstrated that "VEGF and its receptors *flk-1* and *flt-1* may play a role in vascular development and regulation of vascular permeability". At that time, our own various publications were

all confirming that our hope of different specific exclusive functions for flt-1 and flk-1 was not proven :

- Bovine Retinal Endothelial Cells (BRECs) bind VAS-VEGF on two high-affinity binding sites (apparent Kd of 2 and 56 pM) and can proliferate and migrate upon the addition of recombinant VAS-VEGF. (Simorre-Pinatel,..., Plouet et al, Invest Ophthalmol Vis Sci 1994).
- *In vitro*, despite a moderate action on proliferation, VAS/VEGF strongly stimulates cell migration. *In vivo*, VAS/VEGF is a potent inducer of angiogenesis and vascular permeability. (Plouet et Bayard, Horm Res 1994).

We thought that we had obtained anti-idiotypic antibodies recognizing both VEGF receptors known at this time, flt-1 and KDR/flk-1, in accordance with most published findings (cf Annex 1) which did not assign one single function to each receptor. We also thought that these anti-idiotypic antibodies recognized also other growth factor receptors such as those of FGF2 (Fibroblast Growth Factor-basic form or PDGF (Platelet Derived Growth Factor)). The latter was based on the following:

It has been established that subcutaneous injections of highly basic synthetic peptides such as the one encoded by the exon 6 of the long form of PDGF can release endogenous PDGF, which behaves as an auto-antigen, and thus elicit antibodies directed against the exon 6 of PDGF and other sequences of PDGF. The genes of VEGF and PDGF have exactly the same sequences of exon 6; but these sequences are aligned in reverse senses in both genes. This means that eliciting antibodies against VEGF might raise antibodies against VEGF and PDGF. (Raines and Ross, J.Cell.Biol 1992). We were also working of this topic and established that synthetic peptides of exon 6 of VEGF could release endogenous FGF2 from extracellular matrix. These findings were published later on (Jonca,..., Plouet, J.Biol. Chem 97).

From the results published in the 1994 Abstract, we believed, and still do, that the anti-idiotypic antibodies obtained might represent internal images of not only VEGF but also FGF2 released from extracellular matrix.. So, we decided to interrupt this strategy : we had been looking for antibodies

which could help us understand and discriminate between the functions of VEGF receptors. We found ourselves trapped with antibodies inducing both functions, proliferation and migration.

We abandoned this research aimed at finding a true correlation between each receptor and a specific function in angiogenesis, an idea which, even today, is less and less likely to be true. We continued our research on another function of VEGF : In previous years, we had demonstrated with Praloran (Praloran,...,Plouet, CRAS, 1991) that VEGF induced the proliferation of lymphocytes, and thus that VEGF was a true interleukine.



One of the roads we wanted to follow was to induce a vaccination by priming lymphocytes (especially dendritic cells) against VEGF, using anti-idiotypic antibodies of VEGF, hopefully circulating internal images of VEGF, as antigens. But we had to be sure not to produce versatile images, as it seemed to have been the case with the sub-cutaneous immunization.

F. Jonca, a surgeon resident in urology, was working in our laboratory on the role of VEGF in prostatic adenocarcinoma. We chose with him and Praloran to immunize rabbits by injecting VEGF in lymph nodes, hoping to get thus another set of antibodies richer in anti-VEGF. We injected again these antibodies in lymph nodes of other rabbits and we started to analyze the functions of these anti-idiotypic antibodies.

We transfected COS cells with pSV 7d expression plasmids (Quinn et al, PNAS 93) containing the coding sequences of flt-1 and flk-1 and measured the inhibitory activity of anti-idiotypic antibodies towards the binding of iodinated VEGF to these cells, in order to discriminate between true anti-idiotypic antibodies of VEGF and other antibodies representing internal images of other growth factors as the ones we think we obtained during our previous research of a correlation receptor-function.

The results demonstrated that, unexpectedly considering our previous failure to get to specific exclusive functions for each receptor, one of these anti-idiotypic

antibodies was able to bind to KDR/flk-1 but not to flt-1, and to induce cell proliferation but not migration.



A 96 well plate was coated overnight at 4°C with 1.8 µg/ml of anti human Fc (Jackson Immuno research) in 0.05M carbonate buffer pH 9.6, then saturated 2 hours at room temperature with 0.05M carbonate pH 9.6, 0.5% BSA and further incubated with 100ng/ml of either human Fc chimera Flt 1 or human Fc chimera KDR (R&D) 3 hours at room temperature in the same buffer containing 0.05% tween (PBS-TB). Monoclonal antibodies were incubated overnight at 4°C in 100 µl of PBS-TB containing 0.5 µg/ml heparin and 125 pg of iodinated VEGF165. The wells were washed three times with PBS-TB and bound VEGF was removed from plates with 0.5M NaOH and the radioactivity was counted in a gamma counter Packard Cobra. The non specific binding was determined with an excess of unlabeled VEGF (100 ng/ml) and A3 represents an isotype control. The results are expressed as the percentage of specific binding, computed as follows:

$$\text{cpm observed} - \text{non specific binding} / \text{cpm observed in the absence of antibody} - \text{non specific binding}$$

From this immunization of a mouse with the same polyclonal neutralizing antibody anti-VEGF, we derived several

monoclonal anti-idiotypic antibodies. In this figure we show the data corresponding to a set of four monoclonal antibodies of the same isotype. A3 does not bind to any of these two receptors, A9 binds to flt1, and does not bind to flk1. A1 binds to flk1 but not to flt1. A2 binds to both flt1 and flk1.

As a conclusion, we can summarize the following :

1. At the time of the filing of this patent application, a person skilled in the art had learned from most published publications that proliferation and migration (or differentiation) could be induced by the same ligands, or their internal images such as anti-idiotypic antibodies, since there was no clear knowledge of a specific function for each receptor. Conversely, a person skilled in the art following the few publications linking flk-1 with proliferation and flt-1 with migration, would have deduced that the anti-idiotypic antibodies described by the 1994 Abstract, which induced proliferation and migration, were ligands of both flk-1 and flt-1.

2. Although KDR/flk-1 and flt-1 have 50% overall homogeneity, they display 100% homogeneity in some clusters of aminoacids in their extracellular domain :

2.1 It is well admitted that the minimal size of a proteic epitope corresponds to 5-6 contiguous aminoacids or to longer stretches with a single aminoacid difference. If one compares the extracellular domains of KDR/flk-1 (SWISSPROT accession number P35968) and flt-1 (GENPEPT accession number X51602) it appears that sequences 241-247 and 506-511 of KDR/flk-1 are 100% homologous to sequences 246-252 and 511-516 of flt-1. Furthermore sequences 178-184, 300-306 and 695-701 are 85% homologous to 183-189, 305-311 and 700-706 of flt-1.

2.2 It was not clear for someone skilled in the art at the time of the invention, and even today, that KDR/flk-1 is the only receptor responsible for the angiogenic (proliferation, migration and differentiation) process. To blur a concept already not so clear about the functions of each receptor, many publications referred to the "differentiation process", including extracellular matrix digestion, migration, proliferation, and cell organisation in order to form tubes, when showing functional results about the interaction of VEGF

with its receptors. Obviously, other receptors than KDR/flk-1 are involved in the proliferation process.

Patent US5952199, filed as late as June 13, 1997 after the filing of our patent application, from Davis-Smith et al cites in the background of the invention that :

*"Recent gene knockout studies have demonstrated that both the flt-1 and KDR receptors are essential for the normal development of the mammalian vascular system, although their respective roles in endothelial cell proliferation and differentiation appear to be distinct. Thus, the endothelial proliferative and angiogenic activity of the VEGF protein is mediated by binding to the extracellular ligand-binding region of the flt-1 and KDR receptors on the surface of vascular endothelial cells."*

2.3 The 1994 Abstract teaches that anti-idiotypic antibodies of VEGF bind to VEGF receptors. Established data cited above show that these antibodies had certainly to bind to KDR/flk-1 and to flt-1 to induce proliferation and migration. It is highly probable that other receptors known since, such as neuropilin-1 (Soker et al, Cell, 1998) were involved in the growth rate of the prostatic tumor. It has to be reminded that neuropilin-1 is not only expressed by tumor endothelial cells, but also by prostatic cancer cells. Thus, it would not have been *prima facie* obvious for a person skilled in the art to deduct that the antibodies raised would be more likely binding to KDR/flk-1, than to flt-1, neuropilin or other receptors unknown at the time.

2.4 The present invention shows that it is possible to discriminate among antibodies binding to the two receptors KDR/flk-1 and flt-1, some antibodies binding only to one of these receptors. The present invention claims the production of antibodies binding only to KDR/flk-1, and not to flt-1.

2.5 It was not clear for someone skilled in the art at the time of the invention, and even today, that KDR/flk-1 is the only receptor responsible for the angiogenic (proliferation, migration and differentiation) process. Other

receptors are involved. There was no clear evidence linking a specific function to a specific receptor.

2.6 The present invention is the first ever to produce means to activate with no doubt one receptor without activating the other ones. Thus, the contributions of each receptor to each function (proliferation, migration, and differentiation) can be studied and used.

3 The way the antibodies described in the 1994 Abstract were produced is different from the production from the present invention: VEGF was injected in subcutaneous way in the 1994 Abstract antibodies, whereas the antibodies of the present invention are produced by injecting VEGF in lymph nodes. This difference is essential since we can suppose today that subcutaneous immunization against VEGF certainly produced antibodies against VEGF but also other antibodies against FGF and other growth factors epitopes, in particular epitopes corresponding to the binding domains of various growth factors for their receptors.

4. Internalization of the complex " KDR/flk-1 and the claimed antibodies " is the most important property of the antibodies of the invention, which was not taught by the 1994 Abstract.

5. Kieber-Emmons teach that Fab fragments and anti-idiotypic antibodies should exert the same immunogenicity and therefore would equally protect an animal against the same antigen. It is not challenged that vaccines using Fab fragments or the whole anti-idiotypic immunoglobulin would lead to the same vaccinal efficacy.

This purpose is fully different from our claim for bivalent antibodies which can dimerize the receptors of VEGF whereas Fab fragments, which are monovalent, exert an opposite function in endothelial cells : they can only block the VEGF receptors and, in no case, can induce a function similar to that exerted by the anti-idiotypic antibody, namely, receptor dimerization, internalization and cell proliferation.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further



that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

---

Jean Plouet

Date : September , 2000

Annex 1



RECEIVED

SEP 14 2000

TECH CENTER 1600/2900

Publications showing that flt-1 plays a role in proliferation : 5 publications

- Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, Demura H, Yamaguchi S, Shibuya M

Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo.  
J Clin Invest. 1995 Sep;96(3):1295-302.  
PMID: 7657804; UI: 95386684

- Hashimoto M, Ohsawa M, Ohnishi A, Naka N, Hirota S, Kitamura Y, Aozasa K.

Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma.  
Lab Invest. 1995 Dec;73(6):859-63.  
PMID: 8558848; UI: 96109124

- Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH.

Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.  
J Biol Chem. 1994 Oct 28;269(43):26988-95.  
PMID: 7929439; UI: 95014567

- Peters KG, De Vries C, Williams LT.

Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth.  
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8915-9.  
PMID: 7692439; UI: 94022285

- Pavco PA, Bouhana KS ....

Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors  
Clin Cancer Res 2000 May;6(5):2094-103

Publication showing that KDR/flk-1 does not play a role in proliferation :

- Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N.

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.  
J Clin Invest. 1995 Apr;95(4):1789-97.  
PMID: 7535799; UI: 95221633

**Publications showing that KDR/flk-1 plays a role in differentiation, maturation, thus migration : 4 publications**

- Chiang MK, Flanagan JG.

Interactions between the Flk-1 receptor, vascular endothelial growth factor, and cell surface proteoglycan identified with a soluble receptor reagent.  
Growth Factors. 1995;12(1):1-10.  
PMID: 8527158; UI: 96022599

- Flamme I, Breier G, Risau W.

Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo.  
Dev Biol. 1995 Jun;169(2):699-712.  
PMID: 7781909; UI: 95301109

- Oberg C, Waltenberger J, Claesson-Welsh L, Welsh M.

Expression of protein tyrosine kinases in islet cells: possible role of the Flk-1 receptor for beta-cell maturation from duct cells.  
Growth Factors. 1994;10(2):115-26.  
PMID: 7520714; UI: 94347387

- Kendall RL, Thomas KA.

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.  
Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10705-9.  
PMID: 8248162; UI: 94068470

**Publication showing that either KDR/flk1 orflt-1 plays a role in proliferation :**

- Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE.

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.  
Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10457-61.  
PMID: 7479819; UI: 96068634

**Publications showing that KDR/flk1 andflt-1 both play a role in proliferation : 20 publications**

- Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT.

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.  
Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7.  
PMID: 8356051; UI: 93361481

- Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF.

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.  
Cancer Res. 1993 Oct 1;53(19):4727-35.  
PMID: 8402650; UI: 94006261

- Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR.

Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.  
Am J Pathol. 1993 Nov;143(5):1255-62.  
PMID: 8238242; UI: 94056646

- Plate KH, Breier G, Millauer B, Ullrich A, Risau W.

Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.  
Cancer Res. 1993 Dec 1;53(23):5822-7.  
PMID: 7694795; UI: 94061865

- Barleon B, Hauser S, Schollmann C, Weindel K, Marme D, Yayon A, Weich HA.

Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells.  
J Cell Biochem. 1994 Jan;54(1):56-66.  
PMID: 8126087; UI: 94171909

- Plate KH, Breier G, Risau W.

Molecular mechanisms of developmental and tumor angiogenesis.  
Brain Pathol. 1994 Jul;4(3):207-18. Review.  
PMID: 7524960; UI: 95039977

- Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N, Smith SK.

Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells.  
Biol Reprod. 1994 Sep;51(3):524-30.  
PMID: 7803624; UI: 95101869

- Plate KH, Breier G, Weich HA, Mennel HD, Risau W.

Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms.  
Int J Cancer. 1994 Nov 15;59(4):520-9.  
PMID: 7525492; UI: 95048884

- Hatva E, Kaipainen A, Mentula P, Jaaskelainen J, Paetau A, Haltia M, Alitalo K.

Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.  
Am J Pathol. 1995 Feb;146(2):368-78.  
PMID: 7856749; UI: 95160135

- Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML.

Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development.  
Dev Dyn. 1995 May;203(1):80-92.  
PMID: 7647376; UI: 95375314

- Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR.

Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.  
Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5. Review.  
PMID: 7542074; UI: 95337740

- Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G, et al.

Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines.  
Oncogene. 1995 Oct 19;11(8):1569-79.  
PMID: 7478581; UI: 96038884

- Witzigmann-Voos S, Breier G, Risau W, Plate KH.

Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas.  
Cancer Res. 1995 Mar 15;55(6):1358-64.  
PMID: 7533661; UI: 95188174

- Breier G, Clauss M, Risau W.

Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development.  
Dev Dyn. 1995 Nov;204(3):228-39.  
PMID: 8573716; UI: 96127469

- Simon M, Grone HJ, Jöhren O, Kullmer J, Plate KH, Risau W, Fuchs E.

Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney.  
Am J Physiol. 1995 Feb;268(2 Pt 2):F240-50.  
PMID: 7864162; UI: 95168376

- Chakraborty I, Das SK, Dey SK.

Differential expression of vascular endothelial growth factor and its receptor mRNAs in the mouse uterus around the time of implantation.  
J Endocrinol. 1995 Nov;147(2):339-52.  
PMID: 7490564; UI: 96096307

- **Plate KH, Risau W.**

**Angiogenesis in malignant gliomas.  
Glia. 1995 Nov;15(3):339-47. Review.  
PMID: 8586468; UI: 96157538**

- **Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J, Yamamoto H.**

**Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes.  
J Biol Chem. 1995 Nov 24;270(47):28316-24.  
PMID: 7499331; UI: 96081873**

- **Christofori G, Naik P, Hanahan D.**

**Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis.  
Mol Endocrinol. 1995 Dec;9(12):1760-70.  
PMID: 8614412; UI: 96192932**

- **Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ.**

**Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.  
Hum Pathol. 1995 Jan;26(1):86-91.  
PMID: 7821921; UI: 95122077**

**Publications showing KDR/flk1 plays a role in proliferation : 6 publications**

- **Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM.**

Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.  
Cancer Res. 1995 Sep 15;55(18):3964-8.  
PMID: 7664263; UI: 95393389

- **Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK.**

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.  
J Natl Cancer Inst. 1995 Apr 5;87(7):506-16.  
PMID: 7707437; UI: 95222657

- **Flamme I, von Reutern M, Drexler HC, Syed-Ali S, Risau W**

Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation.  
Dev Biol 1995 Oct;171(2):399-414

- **Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC**

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.  
Nature 1995 Jul 6;376(6535):62-6

- **Flamme I, Breier G, Risau W**

Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo.  
Dev Biol 1995 Jun;169(2):699-712

- **Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A**

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.  
Nature 1994 Feb 10;367(6463):576-9

# RESUME

Dr Jean PLOUET

## ◦ *EDUCATION*

### **Medicine**

MD degree, Nantes, 1977.

Certificat d'Etudes Spéciales d'Immunologie, 1977.

Certificat d'Etudes Supérieures d'Immunologie, 1978.

### **Sciences**

Certificat de Biochimie Structurale et Métabolique, Nantes, 1976.

Certificat de Physiologie Animale, Nantes, 1977.

DEA Biochimie Fondamentale, (Option Biologie Moléculaire des Eucaryotes) Paris VII, 1978.

PhD degree. Biochimie Fondamentale, Paris VII, 1981.

Habilitation à Diriger les Recherches. Section 64, Toulouse III, 1992.

## ◦ *APPOINTMENTS*

- 1976 - 1980 : Assistant-Professor in Medical Biochemistry, Nantes University
- 1981 - 1985 : Assistant Research Professor CNRS
  - U.118 INSERM, Paris
  - U.86 INSERM, Paris
- 1987 - 1989 : Assistant Research Biochemist U.C. San Francisco (Cancer Research Institute),
- 1985 - 1991 : Assistant Research Professor with tenure
- 1992 - present : Associate Professor with tenure, Toulouse (UMR CNRS 5089)
- 1999 - present : Head of the Department GDR 1927 CNRS « Angiogénèse »

## ◦ *PUBLICATIONS IN INTERNATIONAL JOURNALS.*

1. Plouët J., Madec Y., 1979.

Détermination du lysozyme dans les liquides biologiques par une technique cinétique semi-automatique. Discussion de la méthode.

Clin. Chim. Acta, 93, 51-60.

2. Feuvray D., Plouët J., 1981.

Relationship between structure and metabolism in mitochondria isolated from ischemic heart.

Circ. Res., 48, 740-747.

3. Barritault D., Plouët J., Courty J., Courtois Y., 1982.

Purification, characterization and biological properties of the eye derived growth factor from retina. Analogies with brain derived growth factor.

J. Neurosc. Res., 8, 477-490.

4. Plouët J., Barritault D., Courtois Y., Ladda R., 1982.

Epidermal growth factor and eye derived growth factor from retina are immunologically distinct and bind to different receptors on human skin fibroblast.

FEBS Lett, 144, 85-93.



5. Romquin N., Plouët J., Barritault D., Courtois Y., 1983.  
Human and bovine vascular endothelial cells. Comparative effects on cell growth and longevity of an eye derived growth factor (EDGF) and of extracellular matrix.  
*Biol. Cell*, 49, 104-108.
6. Plouët J., Courty J., Olivé M., Courtois Y., Barritault D., 1984.  
A highly reliable and sensitive assay for the purification of ocular growth factors.  
*Cell. Mol. Biochem.*, 30, 105-110
7. Petroutsos G., Courty J., Guimaraes R., Pouliquen Y., Barritault D., Plouët J., Courtois Y., 1984.  
Comparison of the effects of EGF, bFGF and EDGF on corneal epithelium wound healing.  
*Curr. Eye Res.*, 3, 573-588.
8. Pfister C., Chabre M., Plouët J., Tuyen V.V., De Kozak Y., Faure J.P., Kühn H., 1985.  
Retinal Santigen identified as the 48k protein regulating light-dependent phosphodiesterase in rods.  
*Science*, 228, 891-893.
9. Fredj-Reygrobellet D., Plouët J., Delayre T., Baudoin C., Bourret F., Lapalus P., 1987.  
Effects of a FGF and bFGF on wound healing in rabbit corneas.  
*Curr. Eye Res.*, 6, 1205-1209.
10. Plouët J., Dorey C., 1987.  
La transduction visuelle.  
*Méd. Sci.*, 3, 192-197.
11. Plouët J., Mascarelli F., Loret M.D., Faure J.P., Courtois Y., 1988.  
Regulation of eye derived growth factor binding to membranes by light ATP or GTP in photoreceptor outer segments.  
*EMBO J.*, 7, 373-376.
12. Globus R.K., Plouët J., Gospodarowicz D., 1989.  
Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix.  
*Endocrinology*, 124, 1539-1547.
13. Plouët J., Gospodarowicz D., 1989.  
Transforming growth factor B positively modulates the bioactivity of fibroblast growth factor on corneal endothelial cells.  
*J. Cell. Physiol.*, 141, 392-399.
14. Gospodarowicz D., Plouët J., Fujii D.K., 1989.  
Ovarian germinal epithelial cells respond to basic fibroblast growth factor and express its gene : implications for early folliculo genesis.  
*Endocrinology*, 125, 1266-1276.
15. Plouët J., Schilling J., Gospodarowicz D., 1989.  
Isolation and characterization of a newly identified endothelial cell mitogen produced by pituitary AT t20 cells.  
*EMBO J.*, 8, 3801-3806.
16. Gospodarowicz D., Plouët J., Mallerstein B., 1990.  
Comparison of the ability of basic and acidic fibroblast growth factor to stimulate the proliferation of an established keratinocyte cell line : modulation of their biological effects by heparin, TGFB and EGF.  
*J. Cell. Physiol.*, 142, 325-333.
17. Plouët J., Gospodarowicz D., 1990.  
Identification of the melanocyte growth factor in iris derived melanocytes.  
*Exp. Eye Res.*, 51, 519-529.

18. Hecquet C., Morisset S., Lorans G., Plouët J., Adolphe M., 1990.  
Effects of acidic and basic fibroblast growth factors on the proliferation of rabbit corneal cells.  
*Curr. Eye Res.*, 9, 429-433.
19. Plouët J., Moukadiri H., 1990.  
Specific binding of vasculotropin to bovine brain capillary endothelial cells.  
*Biochimie*, 72, 51-55.
20. Plouët J., Moukadiri H., 1990.  
Characterization of the receptor to vasculotropin on bovine adrenal cortex derived capillary endothelial cells.  
*J. Biol. Chem.*, 265, 22071-22074.
21. Bikfalvi A., Sauzeau C., Moukadiri H., Josso N., Macclouf J., Plouët J., Tobelem G., 1991.  
Interaction of Vasculotropin with human umbilical vein endothelial cells: binding, internalization, degradation and biological effects.  
*J. Cell. Physiol.*, 149, 50-59.
22. Praloran V., Mirshahi S., Favard C., Moukadiri H., Plouët J., 1991.  
Mitogenic activity of Vasculotropin for peripheral human lymphocytes.  
*CR Acad Sci*, 313, III, 21-26.
23. Favard C., Moukadiri H., Dorey C., Chauvaud D., Praloran V., Plouët J., 1991.  
Purification, cloning, and biological properties of an angiogenic cytokine : the vasculotropin.  
*Biol. Cell*, 73, 1-6.
24. Moukadiri H., Favard C., Praloran V., Plouët J., 1991.  
Vasculotropine: un facteur de croissance angiogénique.  
*Pathol Biol*, 39, 153-156.
25. Chollet P., Malecaze F., Gouzi L., Arné J.L., Plouët J., 1993.  
Endothelin 1 is a growth factor for bovine corneal endothelial cells.  
*Exp. Eye Res.*, 57, 595-600.
26. Midy V., Plouët J., 1994.  
VAS/VEGF induces differentiation in cultured osteoblasts.  
*Biochem. Biophys. Res. Commun.*, 199, 380-386.
27. Simorre-Pinatel V., Guerrin M., Chollet P., Penary M., Clamens S., Malecaze F., Plouët J., 1994.  
Vasculotropin/vascular Endothelial Growth Factor acts on retinal capillary endothelial cells through an autocrine pathway.  
*Invest. Ophthalmol. Vis. Sci.*, 35, 3393-3400.
28. Malecaze F., Clamens S., Simorre-Pinatel V., Chollet P., Mathis A., Favard C., Bayard F., Plouët J., 1994.  
Expression of vasculotropin/vascular endothelial growth factor in vitreous and fibrovascular membranes in diabetic retinopathy.  
*Archiv. Ophthalmol.*, 112, 1476-1482.
29. Plouët J., Bayard F., 1994.  
Regulation of VAS/VEGF bioavailability.  
*Horm. Res.*, 42, 14-19.
30. Guerrin M., Moukadiri H., Chollet P., Moro F., Dutt K., Malecaze F., Plouët J., 1995.  
Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells.  
*J. Cell. Physiol.*, 164, 385-394.

31. Moukadiri H., Gouzi L., Detolle-Sarbach S., Guez D., Plouët J., 1995.  
Inhibition of bFGF and VAS/VEGF biological activities on cultured cells by almitrine.  
*Biochim. Biophys. Acta*, 1265, 168-172.
32. Lachgar S., Moukadiri H., Jonca F., Charveron M., Bouhaddioui N., Gall Y., Bonafé J-L, Plouët J., 1996.  
Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells.  
*J. Invest. Dermatol.*, 106, 17-23.
33. Luty G.A., McLeod S., Merges C., Diggs A., Plouët J., 1996.  
Localization of VEGF in human retina and choroid.  
*Archiv. Ophthalmol.*, 114, 971-977.
34. Ortéga N., Jonca F., Vincent S., Favard C., Malavaud B., Bertrand N., Mazerolles C., Rischmann P., Pouliquen Y., Sarrammon J-P, Ruchoux M-M, Plouët J., 1996.  
Modulation de la progression tumorale par des anticorps anti-idiotypiques de facteurs angiogéniques.  
*CR Acad. Sci.*, III, 319, 411-415.
35. Lachgar S., Charveron M., Gall Y., Plouët J., Bonafé J-L., 1996.  
Vascular endothelial cells: targets for studying the activity growth factor of hair follicle cell-produced VEGF.  
*Cell Biol. Tox.*, 12, 331-334.
36. Favard C., Ortéga N., Bayard F., Plouët J., 1996.  
Vascular endothelial growth factor and retinal neovascularization: a new therapeutic approach for diabetic retinopathy.  
*Diab. & Metab.*, 22, 268-273.
37. Guerrin M., Scottet E., Malecaze F., Houssaint E., Plouët J., 1997.  
Overexpression of vascular endothelial growth factor splice variants 165 and 189 induces cell transformation in cooperation with fibroblast growth factor 2.  
*Oncogene*, 14, 463-471.
38. Bérard M., Sordello S., Ortéga N., Carrier J-L, Peyri N., Wassef O., Bertrand D., Enjolras O., Drouet L., Plouët J., 1997.  
Vascular endothelial growth factor confers to neonatal hemangioma stromal cells a growth advantage in vitro and in vivo.  
*Am. J. Pathol.*, 150, 1315-1326.
39. Jouanneau J., Plouët J., Moens G., Thiéry J.-P., 1997.  
FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo.  
*Oncogene*, 14, 671-676.
40. Plouët J., Moro F., Coldeboeuf N., Bertagnolli S., Clamens S., Bayard F., 1997.  
Extracellular cleavage of the vascular endothelial growth factor 189 aa form by urokinase is required for its mitogenic activity.  
*J. Biol. Chem.*, 272, 13390-13396.
41. Ortéga N., Jonca F., Vincent S., Favard C., Ruchoux M-M, Plouët J., 1997.  
Systemic activation of the vascular endothelial growth factor receptor flk-1 selectively triggers angiogenic endothelial cells.  
*Am. J. Pathol.*, 151, 1215-1224.
42. Jonca F., Ortéga N., Gleizes P.-E., Bertrand N., Plouët J., 1997.  
Cell release of bioactive fibroblast growth factor by exon 6 encoded sequence of vascular endothelial growth factor.  
*J. Biol. Chem.*, 272, 24203-24209.

43. Malavaud B., Tack I., Jonca F., Praddaude F., Moro F., Ader J.-L., Plouët J., 1997.  
Activation of Flk-1/KDR mediates angiogenesis but not hypertension. Direct therapeutic implication in myocardial ischemia.  
Cardiovasc. Res., 36, 276-281.
44. Ortéga N., Sordello S., Plouët J., 1997.  
Vascularisation tumorale: physiopathologie et perspectives thérapeutiques.  
Bull. Cancer, 84, 391-395.
45. Sordello S., Bertrand N., Plouët J., 1998.  
Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens.  
Biochem. Biophys. Res. Commun., 251, 287-290.
46. Ortéga N., L'Faqihi F-E, Plouët J., 1998.  
Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix.  
Biol. Cell, 90, 381-390.
47. Bicknell R., Bikfalvi A., Feige J-J, Plouët J., Ziche M., 1998  
Biology and Physiopathology of angiogenesis.  
Angiogenesis, 2, 51-52.
48. Ortéga N., Hutchings H., Plouët J., 1999.  
Signal relays in the VEGF system.  
Front. Biosci., 4, D141-D152.
49. Jouan V., Canron X., Allemany M., Caen J., Quentin G., Plouët J., Bikfalvi A., 1999.  
Inhibition of in vitro angiogenesis by platelet growth factor-4 derived peptides and mechanism of action.  
Blood, 94, 984-993.
50. Tordjman R., Ortéga N., Coulombel L., Plouët J., Roméo J-P, Lemarchandel V., 1999.  
Neuropilin-1 is expressed on bone marrow stromal cells : a novel interaction between stroma and haematopoietic cells.  
Blood, 94, 2301-2309.
51. Okada-Ban M, Plouët J., Thiéry JP, Jouanneau J., 1999.  
Impact on tumor angiogenesis and tumor progression of expression of the 18 kd and 24 kd isoforms of FGF-2.  
Pathol Biol, 1999, 47, 375-379.
52. Binétruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., Plouët J., Derbin C., Perret G., Mazié JC, 2000.  
Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis  
EMBO J., 19, 1525-1533.
53. Concina P, Sordello S., Elhage N., Fournial P., Plouët J., Bayard F., Arnal J-F, 2000 .  
The mitogenic effect of 17  $\beta$ -Estradiol on in vitro endothelial cell proliferation and on in vivo reendothelialization are both dependent on VEGF.  
J. Vasc. Res., 37, 202-208.
54. Midy V., Hollande E., Rey C., Dard M., Plouët J., 1999.  
Calcium phosphate ceramics as a controlled release system for vascular endothelial growth factor.  
J. Biomed, Mat. Res., sous presse.

◦ **REVIEWS IN FRENCH JOURNALS.**

1. Barritault D., Arruti C., Plouët J., Olivié M., Courtois Y., 1980.  
Culture cellulaire et facteurs de croissance. Intérêt en ophtalmologie.  
Journal Français d'Ophtalmologie, 34, 54-59..
2. Plouët J., 1982.  
Des cellules pour éviter l'animal.  
Sciences et Avenir, 37, 64-67.
3. Plouët J., Courty J., Barritaut D., Courtois Y., 1983.  
Les facteurs de croissance cellulaire sont-ils un nouvel outil permettant d'obtenir des modèles expérimentaux in vitro proches de la situation physiologique ? Application à la recherche ophtalmologique.  
Science et Techniques de l'Animal de laboratoire, 1, 11-15.
4. Plouët J., 1991.  
Mécanismes d'action et de sécrétion de la vasculotropine  
Lettres Bio - CNRS, 23, 6.
5. Favard C, Lamrani C., Chauvaud D., Gaudric A., Plouët J., 1991.  
Comparison of angiogenic activity of Vasculotropin and FGF in the corneal pocket assay.  
Ophtalmologie, 6, 118-121
6. Malecaze F., Chollet P., Plouët J., Mathis A., Arné J.L., 1992.  
Les facteurs de croissance en ophtalmologie.  
Journal Français d'Ophtalmologie, 15, 621-632.
7. Coldeboeuf N., Malavaud B., Jonca F., Plouët J., 1993.  
Biodisponibilité de la vasculotropine dans l'adénome et l'adénocarcinome prostatiques.  
Bulletin de l'Association de recherche sur les tumeurs de prostate, 11, 1-
8. Simorre-Pinatel V., Malecaze F., Chollet P., Guerrin M., Plouët J., 1995.  
Action in vitro de la vasculotropine sur les cellules de capillaires rétiens.  
Ophtalmologie, 9, 135-138.
9. Sordello S., Malavaud B., Plouët J., 1997.  
Angiogenèse et progression tumorale des adénocarcinomes prostatiques.  
Bulletin de l'Association de recherche sur les tumeurs de prostate, 22, 37-40.
10. Bicknell R., Bikfalvi A., Feige J-J, Plouët J., Ziche M., 1998  
Biologie et Physiopathologie de l'angiogénèse.  
Sang, Thrombose et Vaisseaux, 10, 186-188.
11. Plouët J., 1998.  
A propos de : les facteurs de croissance s'attaquent à la maladie coronaire.  
Abstract Cardio, 306, 4-5.
12. Plouët J., 1998.  
Le rôle de l'angiogenèse dans la formation des métastases.  
Métastases et Os, 1, 8-13.
13. Plouët J., 1999.  
L'angiogenèse en 1999.  
Pathol Biol, 47, 300.

14. Plouët J., 1999.  
Facteurs angiogéniques et croissance tumorale  
Ann. Pathol, 19, S70-71.

15. Malavaud B., Plouët J., 2000.  
Nouvelle perspective thérapeutique en cancérologie : l'anti-angiogénèse.  
Bull. Acad Med, 184, 579-587.

## ◦ **CHAPTERS IN BOOKS**

1. Thompson P., Arruti C., Maurice D., Plouët J., Barritault D., Courtois Y., 1982.  
Angiogenic activity of a cell growth regulating factor derived from the retina. In : "Problems of Normal and Genetically Abnormal Retinas". R. Clayton ed., Acad Press, New York, 61-78.

2. Courtois Y., Arruti C., Barritault D., Courty J., Tassin J. Olivé M., Plouët J., Laurent M., Perry M., 1983.

The role of a growth factor derived from the retina (EDGF) in controlling the differentiated stages of several ocular and non ocular tissues. In "Regulability of the Differentiated State". R. Clayton and D.E.S. Truman eds., Acad. Press, New York, 289-306.

3. Barritault D., Plouët J., Courty S., Courtois Y., 1983.

Purification, characterization and biological properties of the eye derived growth factor from retina. Analogies with brain derived growth factor.

Progress in Clinical and Biological Research, Alan R. Liss Ed., 118.

4. Plouët J., Olivé M., Courtois J., Courtois Y., Barritault D. (1983).

Use of Eye Derived Growth Factor from retina (EDGF) in culture medium for the culture of bovine epithelial lens cells.

Proceedings of the "First European Conference on Serum-Free Cell Culture", 123-126.

5. Plouët J., Mascarelli F., Lagente D., Dorey C., Lorans G., Faure J.P., Courtois Y., 1986.

Eye-derived growth factor : a component of rod outer segment implicated in phototransduction.

In Retinal Signal Systems, Degenerations and Transplants. E. Agardh and B. Ehringer, Eds. Elsevier, Amsterdam, pp. 311-320.

6. Plouët J., 1988.

Molecular interactions of fibroblast growth factor, light activated rhodopsin and Santigen. In Molecular Biology of the Eye : genes, vision and ocular disease.

UCLA Symposia on Molecular and Cellular Biology, New Series, Vol 88, J. Piatigorsky, P. Zelenka, and L. Shinohara. Eds, R. Alan R. Liss, New York, p. 83-92.

7. Hamel C., Moukadiri H., Favard C., Dorey C., Plouët J., 1990

Rôles de l'épithélium pigmenté de la rétine dans la maturation des photorecepteurs.

"Physiologie, Pathologie et génétique oculaires", Séminaires Ophtalmologiques Ipsen, Tome 2, Christen F., Doly M., Droix-Lefaix M.T. Eds, Springer-Verlag, 123-131.

8. Moukadiri H., Favard C., Bikfalvi A., Plouët J., 1992.

Biosynthesis of vasculotropin and expression of vasculotropin receptors by cultured cells.

In Symposium on Biotechnology of Growth factors, Lenfant C., Paoletti R., Albertini A. eds, Karger, 123-128.

9. Plouët J., Moukadiri H., Gouzi L., Malavaud B., Ruchoux M.-M., 1992.

Vasculotropin/VEGF hypersecretion by vascular smooth muscle cells from spontaneously hypertensive rats.

In "Genetic hypertension" J. Sasser ed, INSERM-Libbey, 218, 207-209.

10. Favard C, Maret A, Prats H, Plouët J, Bayard F., 1995.  
Growth factors binding heparin: FGF and VEGF. Physiological and physiopathological importance.  
Therapeutic implications in diabetic retinopathy.  
Journées Annuelles de Diabetologie de l' Hotel Dieu, 1995, 1, 39-51.
11. Plouët J., Sordello S., Malavaud B., Ortéga N., 1996.  
VEGF and breast cancer.  
Breast cancer. Advances in biology and therapeutics. F. Calvo, M. Crépin, H. Magdalenat, eds. John Libbey Eurotext 175-181.
12. Plouët J., Malavaud B., Sordello S., Ortéga N., 1996.  
Rôles du VEGF dans la progression tumorale.  
Eurocancer 96, 197-198 ; M. Boiron, M. Marty eds. John Libbey Eurotext.
13. Sordello S., Faucon B., Plouët J., 1998.  
Rôles du VEGF et de ses récepteurs dans l'angiogénèse du cancer du sein.  
In "Du dépistage au diagnostic précoce : le cancer du sein aujourd'hui. Diagnostic, pronostic, traitement." M. Bolla, F. Vincent ED, Arnette Editions, 107-113.
14. Sordello S., Fons P., Malavaud B., Plouët J., 2000.  
VEGF family  
Comprehensive vascular Biology and pathology-An Encyclopedic Reference. A. Bikfalvi Ed, Springer-Verlag, 322-331.
15. Hutchings H., Ortéga N., Tournier J-F, Plouët J., 2000.  
Endothelial cells.  
Comprehensive vascular Biology and pathology-An Encyclopedic Reference. A. Bikfalvi Ed, Springer-Verlag, 80-85.